Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Lars, Weidolf"'
Autor:
Xue‐Qing Li, Bo Lindmark, Carl Amilon, Kristin Samuelsson, Lars Weidolf, Karin Nelander, Jane Knöchel, Maria Heijer, Ryan A. Bragg, Malin Gränfors, Eva‐Lotte Lindstedt, Sharan Sidhu, Pavlo Garkaviy, Hans Ericsson
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 5, Pp n/a-n/a (2024)
Abstract In this study, the mass balance, pharmacokinetics (PK) and metabolism of atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor, were investigated in healthy male subjects. A single oral dose of 200 mg [14C]atuliflapon suspensi
Externí odkaz:
https://doaj.org/article/76c37c93a11c42119bf483510f8f49aa
Autor:
Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf, V. Sashi Gopaul
Publikováno v:
Drug Metabolism and Disposition. 51:451-463
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e32d1617b5bd8c510ddc429b7c85fe93
https://doi.org/10.1124/dmd.122.001100
https://doi.org/10.1124/dmd.122.001100
Autor:
Lars Weidolf, Xue-Qing Li, Anders Dahlén, Shalini Andersson, Marie Elebring, David Janzén, Peter Gennemark, Mikko Hölttä, Anders Björkbom
Publikováno v:
Drug Discovery Today. 26:2244-2258
Drug properties of antisense oligonucleotides (ASOs) differ significantly from those of traditional small-molecule therapeutics. In this review, we focus on ASO disposition, mainly as characterized by distribution and biotransformation, of nonconjuga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dfa10ddbbcf8fc64d9301ad8e2eed58
https://doi.org/10.1016/j.drudis.2021.04.002
https://doi.org/10.1016/j.drudis.2021.04.002
Publikováno v:
Xenobiotica. 51:1081-1086
1. Challenges and opportunities in the field of biotransformation were presented and discussed at the 1st European Biotransformation workshop which was conducted virtually in collaboration with the DMDG 27 January 2021. Here we summarize the presenta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f760eb8345e3e619031a31662c9e0f8
https://doi.org/10.1080/00498254.2021.1958027
https://doi.org/10.1080/00498254.2021.1958027
Autor:
Ann Aurell Holmberg, Alexandra Jauhiainen, Rianne A F de Ligt, Ioannis Psallidas, Ulrika Wählby Hamrén, Marta Pelay-Gimeno, Elwin Verheij, Bold Peter, Sharan Sidhu, Sofia Necander, Lars Weidolf, Susanne Prothon
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 50(2)
This open-label, single-period study describes the human absorption, distribution, metabolism, excretion and pharmacokinetics of velsecorat (AZD7594). Healthy subjects received inhaled velsecorat (non-radiolabeled; 720 µg) followed by intravenous (I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e12a48b2e5a82e39c2bfe73c7ec0630b
https://pubmed.ncbi.nlm.nih.gov/34853068
https://pubmed.ncbi.nlm.nih.gov/34853068
Autor:
Lars Weidolf, Eva-Henriette Bangur, Gunnar Gronberg, Neal Castagnoli, Xue-Qing Li, Martin A. Hayes
Publikováno v:
Drug Metabolism and Disposition. 47:1247-1256
AZD1979 [(3-(4-(2-oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone] is a melanin-concentrating hormone receptor 1 antagonist designed for the treatment of obesity. In this study, metabolit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c21d815a7a1c575c7b5e54e0b467b739
https://doi.org/10.1124/dmd.119.088658
https://doi.org/10.1124/dmd.119.088658
Publikováno v:
Drug Discovery Today. 23:1733-1745
Oligonucleotide and modified mRNA therapeutics have great potential to treat diseases that are currently challenging to cure and are expanding into global and chronic disease areas such as cancer and various cardiovascular diseases. Advanced drug del
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::632b19063abf397c0322855babe06b67
https://doi.org/10.1016/j.drudis.2018.05.030
https://doi.org/10.1016/j.drudis.2018.05.030
Autor:
Yoshio Morikawa, Ian D. Wilson, Matthew Baginski, Richard A. Thompson, Lars Weidolf, Anja Ekdahl
Publikováno v:
Archives of Toxicology
The metabolic fate of the human hepatotoxin fenclozic acid ([2-(4-chlorophenyl)-1,3-thiazol-4-yl]acetic acid) (Myalex) was studied in normal and bile-cannulated chimeric mice with a humanized liver, following oral administration of 10 mg/kg. This in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4ca68bb88f74e638cee48f7bfdd949a
https://doi.org/10.1007/s00204-018-2274-0
https://doi.org/10.1007/s00204-018-2274-0
Autor:
Xue-Qing Li, Francesca Toselli, Peder Svensson, Martin A. Hayes, Lars Weidolf, Anders Johansson, Marlene Fredenwall
Publikováno v:
Journal of medicinal chemistry. 62(16)
Oxetane-containing ring systems are increasingly used in medicinal chemistry programs to modulate druglike properties. We have shown previously that oxetanes are hydrolyzed to diols by human microsomal epoxide hydrolase (mEH). Mapping the enzymes tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc2f8b2d23ca6260c52683e5149df784
https://pubmed.ncbi.nlm.nih.gov/31310524
https://pubmed.ncbi.nlm.nih.gov/31310524
Autor:
Kristina Berggren, Lars Weidolf, Martin A. Hayes, Gunnar Gronberg, Neal Castagnoli, Xue-Qing Li
Publikováno v:
Drug Metabolism and Disposition. 44:1341-1348
Oxetane moieties are increasingly being used by the pharmaceutical industry as building blocks in drug candidates because of their pronounced ability to improve physicochemical parameters and metabolic stability of drug candidates. The enzymes that c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7689e52373795731f1b36233b758fd91
https://doi.org/10.1124/dmd.116.071142
https://doi.org/10.1124/dmd.116.071142